← All trials
NCT07154316
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2025
- Primary completion
- Aug 1, 2028
- Completion date
- Dec 30, 2028
- First posted
- Sep 4, 2025
- Last posted
- Sep 4, 2025
- Enrollment
- 138
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Cancer Hospital of Yunnan provincealCollaborator
- Anyang Regional HospitalCollaborator
- Fudan UniversitySponsor investigator
- Shandong first medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.